Name | Number of supported studies | Average coverage | |
---|---|---|---|
peripheral blood | 22 studies | 92% ± 14% | |
lung | 21 studies | 82% ± 22% | |
brain | 20 studies | 52% ± 21% | |
intestine | 15 studies | 78% ± 28% | |
eye | 11 studies | 71% ± 22% | |
liver | 9 studies | 65% ± 28% | |
kidney | 9 studies | 81% ± 22% | |
lymph node | 7 studies | 94% ± 10% | |
bone marrow | 6 studies | 82% ± 21% | |
heart | 6 studies | 35% ± 17% | |
uterus | 6 studies | 80% ± 28% | |
pancreas | 5 studies | 83% ± 21% | |
prostate | 5 studies | 70% ± 36% | |
placenta | 4 studies | 86% ± 20% | |
adipose | 4 studies | 50% ± 26% | |
esophagus | 4 studies | 63% ± 29% | |
skin | 4 studies | 81% ± 28% | |
breast | 4 studies | 96% ± 4% | |
ovary | 3 studies | 76% ± 31% | |
adrenal gland | 3 studies | 84% ± 16% | |
stomach | 3 studies | 66% ± 21% | |
thymus | 3 studies | 79% ± 30% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
intestine | 100% | 40087.91 | 966 / 966 | 100% | 1048.94 | 527 / 527 |
ovary | 100% | 41507.37 | 180 / 180 | 100% | 1225.39 | 430 / 430 |
stomach | 100% | 27188.28 | 359 / 359 | 100% | 983.30 | 286 / 286 |
esophagus | 100% | 33783.56 | 1444 / 1445 | 100% | 805.30 | 183 / 183 |
breast | 100% | 42062.50 | 459 / 459 | 100% | 724.05 | 1116 / 1118 |
thymus | 100% | 42123.43 | 653 / 653 | 100% | 900.89 | 603 / 605 |
lung | 100% | 37337.65 | 576 / 578 | 100% | 745.40 | 1155 / 1155 |
bladder | 100% | 35209.57 | 21 / 21 | 100% | 791.19 | 502 / 504 |
prostate | 100% | 28510.75 | 245 / 245 | 100% | 496.55 | 500 / 502 |
uterus | 100% | 44981.83 | 170 / 170 | 100% | 954.30 | 457 / 459 |
pancreas | 100% | 24231.76 | 327 / 328 | 99% | 618.39 | 176 / 178 |
skin | 100% | 47887.42 | 1809 / 1809 | 99% | 502.72 | 465 / 472 |
brain | 100% | 21277.62 | 2630 / 2642 | 99% | 343.76 | 695 / 705 |
kidney | 100% | 32235.09 | 89 / 89 | 96% | 468.77 | 867 / 901 |
adrenal gland | 100% | 19208.89 | 258 / 258 | 88% | 249.23 | 202 / 230 |
liver | 92% | 12670.58 | 207 / 226 | 93% | 298.85 | 377 / 406 |
adipose | 100% | 45545.32 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 50764.73 | 1335 / 1335 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 880.69 | 29 / 29 |
spleen | 100% | 33529.24 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 1049.40 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 583.08 | 1 / 1 |
eye | 0% | 0 | 0 / 0 | 96% | 422.15 | 77 / 80 |
heart | 87% | 11957.21 | 745 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 84% | 34661.65 | 777 / 929 | 0% | 0 | 0 / 0 |
muscle | 53% | 5129.23 | 425 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0006351 | Biological process | DNA-templated transcription |
GO_0043066 | Biological process | negative regulation of apoptotic process |
GO_0045944 | Biological process | positive regulation of transcription by RNA polymerase II |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005829 | Cellular component | cytosol |
GO_0005634 | Cellular component | nucleus |
GO_0140297 | Molecular function | DNA-binding transcription factor binding |
GO_0005515 | Molecular function | protein binding |
GO_0042393 | Molecular function | histone binding |
Gene name | PTMA |
Protein name | Prothymosin alpha Prothymosin alpha [Cleaved into: Prothymosin alpha, N-terminally processed; Thymosin alpha-1] |
Synonyms | TMSA PTMAP7 |
Description | FUNCTION: Prothymosin alpha may mediate immune function by conferring resistance to certain opportunistic infections. FUNCTION: Prothymosin alpha may mediate immune function by conferring resistance to certain opportunistic infections. . FUNCTION: Prothymosin alpha may mediate immune function by conferring resistance to certain opportunistic infections. . FUNCTION: Prothymosin alpha may mediate immune function by conferring resistance to certain opportunistic infections. . FUNCTION: Prothymosin alpha may mediate immune function by conferring resistance to certain opportunistic infections. . FUNCTION: Prothymosin alpha may mediate immune function by conferring resistance to certain opportunistic infections. . FUNCTION: Prothymosin alpha may mediate immune function by conferring resistance to certain opportunistic infections. . FUNCTION: Prothymosin alpha may mediate immune function by conferring resistance to certain opportunistic infections. . FUNCTION: Prothymosin alpha may mediate immune function by conferring resistance to certain opportunistic infections. . |
Accessions | ENST00000409683.5 B8ZZA1 P06454 B8ZZQ6 ENST00000409321.5 Q8TBK9 H7C031 F8WCE8 Q7KZ52 Q53S24 Q9NYD3 ENST00000410064.5 ENST00000409115.8 [P06454-2] B8ZZW7 H7C2N1 ENST00000440384.1 Q15254 ENST00000341369.11 [P06454-1] ENST00000448874.5 ENST00000412128.1 |